Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the target of a large growth in short interest in January. As of January 31st, there was short interest totalling 6,880,000 shares, a growth of 19.4% from the January 15th total of 5,760,000 shares. Based on an average daily volume of 2,010,000 shares, the days-to-cover ratio is currently 3.4 days.

Institutional Investors Weigh In On Adaptimmune Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Two Seas Capital LP bought a new position in shares of Adaptimmune Therapeutics in the 4th quarter valued at about $7,992,000. Long Focus Capital Management LLC boosted its stake in shares of Adaptimmune Therapeutics by 54.1% in the 4th quarter. Long Focus Capital Management LLC now owns 20,494,393 shares of the biotechnology company’s stock valued at $11,040,000 after purchasing an additional 7,194,503 shares during the last quarter. Baillie Gifford & Co. boosted its stake in shares of Adaptimmune Therapeutics by 10.7% in the 3rd quarter. Baillie Gifford & Co. now owns 16,775,860 shares of the biotechnology company’s stock valued at $15,944,000 after purchasing an additional 1,626,657 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Adaptimmune Therapeutics by 52.5% in the 4th quarter. Renaissance Technologies LLC now owns 2,526,524 shares of the biotechnology company’s stock valued at $1,361,000 after purchasing an additional 869,949 shares during the last quarter. Finally, Jane Street Group LLC boosted its stake in shares of Adaptimmune Therapeutics by 87.7% in the 4th quarter. Jane Street Group LLC now owns 326,937 shares of the biotechnology company’s stock valued at $176,000 after purchasing an additional 152,780 shares during the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Trading Up 0.3 %

ADAP opened at $0.58 on Monday. The company has a current ratio of 3.85, a quick ratio of 3.82 and a debt-to-equity ratio of 0.62. The stock has a market capitalization of $147.90 million, a PE ratio of -2.63 and a beta of 2.42. Adaptimmune Therapeutics has a 1-year low of $0.53 and a 1-year high of $2.05. The firm has a 50-day moving average price of $0.60 and a two-hundred day moving average price of $0.81.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on ADAP. HC Wainwright dropped their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a research report on Thursday, November 14th. StockNews.com cut shares of Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Mizuho dropped their target price on shares of Adaptimmune Therapeutics from $3.00 to $1.50 and set an “outperform” rating for the company in a research report on Wednesday, November 27th. Finally, Guggenheim dropped their target price on shares of Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $2.79.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.